A case study of 10 patients administered HBOC-201 in high doses over a prolonged period: outcomes during severe anemia when transfusion is not an option

Transfusion

Volumn 60, Issue 5, 2020, Pages 932-939

  Zumberg, Marc ^a   Gorlin, Jed ^b   Griffiths, Elizabeth A ^c   Schwartz, Garry ^d   Fletcher, Bradley S ^a   Walsh, Katherine ^e   Dao, Kim Hien ^f   Vansandt, Amanda ^f   Lynn, Mauricio ^g   Shander, Aryeh ^h  

^a University of Florida Shands Cancer Hospital ^*  (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d Levine Cancer Institute   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; POLYMERIZED HEMOGLOBIN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CARBOXIHEMOGLOBINEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; DRUG SAFETY; DYSPHAGIA; ESOPHAGUS SPASM; FEMALE; GASTROINTESTINAL SYMPTOM; GEOGRAPHY; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOXEMIA; INFORMED CONSENT; MALE; METHEMOGLOBINEMIA; MIDDLE AGED; NAUSEA; OBSERVATIONAL STUDY; PERIPHERAL EDEMA; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN DISCOLORATION; TREATMENT DURATION; TREATMENT OUTCOME; YOUNG ADULT; BLOOD TRANSFUSION REACTION; CONTRAINDICATION; DOSE RESPONSE; DRUG ADMINISTRATION; LONG TERM CARE; PATHOLOGY; PROCEDURES; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

ADULT; AGED; ANEMIA; BLOOD TRANSFUSION; COHORT STUDIES; CONTRAINDICATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBINS; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRANSFUSION REACTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85084870275     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.15778     Document Type: Article

References (50)

1. Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion: a clinical practice guideline from the AABB*. Ann Intern Med 2012;157:49-58.
2. Dubé GP, Pitman AN, Mackenzie CF. Relative efficacies of HBOC-201 and polyheme to increase oxygen transport compared to blood and crystalloids. “2017 Military Supplement.”. Shock 2017;52(Suppl 1):100-7.
3. Mullier F, Lessire S, De Schoutheete JC, et al. Facing coagulation disorders after acute trauma. B-ENT 2016;26:67-85.
4. Weiskopf RB, Beliaev AM, Shander A, et al. Addressing the unmet need of life-threatening anemia with hemoglobin-based oxygen carriers. Transfusion 2017;57:207-14.
5. Jahr JS, Mackenzie C, Pearce LB, et al. HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery. J Trauma 2008;64:1484-97.
6. Moore EE, Moore FA, Fabian TC, et al. Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial. J Am Coll Surg 2009;208:1-13.
7. Greenburg AG, Light WR, Dubé GP. Reconstructing hemoglobin-based oxygen carriers. Transfusion 2010;50:2764-7.
8. Keipert PE, Olofsson C, Winslow RM. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA 2008;300:1295-6.
9. Levien LJ, Hodgson RE, James MF. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA 2008;300:1295-9.
10. Shander A, Javidroozi M, Thompson G. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA 2008;300:1296-7.
11. Silverman TA, Weiskopf RB. Hemoglobin-based oxygen carriers: current status and future directions. Transfusion 2009;49:2495-515.
12. Garcia-Ruiz JM, Galan-Arriola C, Fernandez-Jimenez R, et al. Bloodless reperfusion with the oxygen carrier HBOC-201 in acute myocardial infarction: a novel platform for cardioprotective probes delivery. Basic Res Cardiol 2017;112:17.
13. Meliga E, Vranckx P, Regar E, et al. Proof-of-concept trial to evaluate haemoglobin based oxygen therapeutics in elective percutaneous coronary revascularization. Rationale, protocol design and haemodynamic results. EuroIntervention 2008;4:99-107.
14. Mongan PD, Moon-Massat PF, Rentko V, et al. Regional blood flow after serial normovolemic exchange transfusion with HBOC-201 (Hemopure) in anesthetized swine. J Trauma 2009;67:51-60.
15. Muir WW, Ilangovan G, Zweier JL, et al. Vital organ tissue oxygenation after serial normovolemic exchange transfusion with HBOC-201 in anesthetized swine. Shock 2011;35:597-603.
16. Serruys PW, Vranckx P, Slagboom T, et al. Haemodynamic effects, safety, and tolerability of haemoglobin-based oxygen carrier-201 in patients undergoing PCI for CAD. EuroIntervention 2008;3:600-9.
17. Taverne YJ, de Wijs-Meijler D, Te Lintel HM, et al. Normalization of hemoglobin-based oxygen carrier-201 induced vasoconstriction: targeting nitric oxide and endothelin. J Appl Physiol (1985) 2017;122:1227-37.
18. Te Lintel HM, Dube GP, Regar E, et al. Preoxygenated hemoglobin-based oxygen carrier HBOC-201 annihilates myocardial ischemia during brief coronary artery occlusion in pigs. Am J Physiol Heart Circ Physiol 2010;298:H1103-13.
19. Dubé GP, Vranckx P, Greenburg AG. HBOC-201: the multi-purpose oxygen therapeutic. EuroIntervention 2008;4:161-5.
20. [accessed 2020 Jan 9] Available from: https://www.fda.gov/news-events/public-health-focus/expanded-acces.
21. Mackenzie CF, Moon-Massat PF, Shander A, et al. When blood is not an option: factors affecting survival after the use of a hemoglobin-based oxygen carrier in 54 patients with life-threatening anemia. Anesth Analg 2010;110:685-93.
22. Mackenzie CF, Dubé GP, Pitman A, et al. Users guide to pitfalls and lessons learned about HBOC-201 during clinical trials, expanded access, and clinical use in 1,701 patients. Shock 2017;52(Suppl 1):92-99.
23. Levien LJ. South Africa: clinical experience with hemopure. ISBT Sci Ser 2006:167-73.
24. Beliaev AM, Marshall RJ, Gordon M, et al. Clinical benefits and cost-effectiveness of allogeneic red-blood-cell transfusion in severe symptomatic anaemia. Vox Sang 2012;103:18-24.
25. Hamilton RG, Kickier T. Bovine hemoglobin (Glutamer-250 Hemopure) specific IgG antibody cross-reacts with human hemoglobin hut does not lyse RBCs in vitro. Transfusion 2007;47:723-8.
26. Meledeo MA, Peltier GC, McIntosh CS, et al. Freeze-dried plasma mitigates the dilution effects of a hemoglobin-based oxygen carrier (HBOC-201) in a model of resuscitation for hemorrhage and hemodilution. J Trauma Acute Care Surg. 2019;87(1S Suppl 1):S83-90.
27. Stensballe J, Henriksen HH, Johansson PI. Early haemorrhage control and management of trauma-induced coagulopathy: the importance of goal-directed therapy. Curr Opin Crit Care 2017;23:503-10.
28. Kabat GC, Kim MY, Verma AK, et al. Association of hemoglobin concentration with total and cause-specific mortality in a cohort of postmenopausal women. Am J Epidemiol 2016;183:911-9.
29. Mer M, Hodgson E, Wallis L, et al. Hemoglobin glutamer-250 (bovine) in South Africa: consensus usage guidelines from clinician experts who have treated patients. Transfusion 2016;56:2631-6.
30. Salmen M, Hendriksen S, Gorlin J, et al. Oxygen delivery during severe anemia when blood transfusion is refused on religious grounds. Ann Am Thorac Soc 2017;14:1216-20.
31. Robertson BE, Schubert R, Hescheler J, et al. cGMP-dependent protein kinase activates Ca-activated K channels in cerebral artery smooth muscle cells. Am J Physiol 1993;265:C299-303.
32. Walter U. Physiological role of cGMP and cGMP-dependent protein kinase in the cardiovascular system. Rev Physiol Biochem Pharmacol 1989;113:41-8.
33. Guyton AC, Hall JE. Heart muscle: the heart as a pump. Texbook of medical physiology. 10th ed. Philadelphia, PA: W.B. Saunders Co; 2000. p. 96-107.
34. Guyton AC, Hall JE. Nervous regulation of the circulation and rapid control of arterial pressure. Texbook of medical physiology. 10th ed. Philadelphia, PA: W.B. Saunders Co; 2000. p. 184-94.
35. Groneberg D, Voussen B, Friebe A. Integrative control of gastrointestinal motility by nitric oxide. Curr Med Chem 2016;23:2715-35.
36. Yamato S, Saha JK, Goyal RK. Role of nitric oxide in lower esophageal sphincter relaxation to swallowing. Life Sci 1992;50:1263-72.
37. Sifrim D, Lefebvre R. Role of nitric oxide during swallow-induced esophageal shortening in cats. Dig Dis Sci 2001;46:822-30.
38. Hull TD, Agarwal A, George JF. The mononuclear phagocyte system in homeostasis and disease: a role for heme oxygenase-1. Antioxid Redox Signal 2014;20:1770-88.
39. Origassa CS, Câmara NO. Cytoprotective role of heme oxygenase-1 and heme degradation derived end products in liver injury. World J Hepatol 2013;27:5:541-9.
40. Page TC, Light WR, McKay CB, et al. Oxygen transport by erthyrocyte/hemoglobin solution mixtures in an in vitro capillary as a model of hemoglobin based oxygen carrier performance. Microvasc Res 1998;55:54-64.
41. Standl T, Horn P, Wilhelm S, et al. Bovine haemoglobin is more potent than autologous red blood cells in restoring muscular tissue oxygenation after profound isovolaemic haemodilution in dogs. Can J Anaesth 1996;43:714-23.
42. Scott EM, McGraw JC. Purification and properties of diphosphopyridine nucleotide diaphorase of human erythrocytes. J Biol Chem 1962;237:249-52.
43. Darling AU, Roughton R. The effect of methemoglobin on the equilibrium between oxygen and hemoglobin. Am J Physiol 1942;137:56-68.
44. Simoni J, Villanueva-Meyer J, Simoni G, et al. Control of oxidative reactions of hemoglobin in the design of blood substitutes: role of the ascorbate-glutathione antioxidant system. Artif Organs 2009;33:115-26.
45. Bessereau J, Aboab J, Hullin T, et al. Safety of hyperbaric oxygen therapy in mechanically ventilated patients. Int Marit Health 2017;68:46-51.
46. Levy JH. The use of haemoglobin glutamer-250 (HBOC-201) as an oxygen bridge in patients with acute anaemia associated with surgical blood loss. Expert Opin Biol Ther 2003 Jun;3:509-17. Review. Erratum in: Expert Opin Biol Ther. 2003 Sep;3(6):1017.
47. Kwok CS, Tiong D, Pradhan A, et al. Meta-analysis of the prognostic impact of anemia in patients undergoing percutaneous coronary intervention. Am J Cardiol 2016;118:610.
48. Weiskopf RB, Silverman TA. Balancing potential risks and benefits of hemoglobin-based oxygen carriers. Transfusion 2013;53:2327-33.
49. Natanson C, Kern SJ, Lurie P, et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 2008;299:2304-12.
50. Van Hemelrijck J, Levien LJ, Veeckman L, et al. A safety and efficacy evaluation of hemoglobin-based oxygen carrier HBOC-201 in a randomized, multicenter red blood cell controlled trial in noncardiac surgery patients. Anesth Analg 2014;119:766-76.